Great investor presentation (again).
Interesting to note the parameters and subs aspired by our imminent breastcancer phase 1 complete data sets.
ORR >25%, and pCR>16% (11-22).
May be worth a re-visit to the 1b top line results for some (encouraging indeed).
Also, would like to know the progress of the ptx-100 orphan drug application.
As our CEO stated’ multiple shots at goal’.
Luck to all holders.
Ann: March 2018 Investor Presentation, page-2
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
